A patient arrives in the emergency department with pinpoint pupils, slowed breathing, and the clinical profile of an opioid overdose, yet the opioid screen comes back negative. The only clue is an empty bottle labeled Neptune’s Fix in a jacket pocket, a product the standard panel was never built to catch.
Tianeptine does not show up on standard 5, 10, or 12-panel urine drug screens. The substance, sold in U.S. convenience stores, vape shops, and online under brand names including Tianaa, Zaza, Neptune’s Fix, Pegasus, and TD Red, produces opioid-like clinical effects despite being structurally distinct from heroin, fentanyl, and morphine. That mismatch between presentation and routine analytical capability has become a recurring problem in poison center logs, emergency departments, and forensic casework, and it is the focus of accelerating federal and state action through 2025.
The trajectory has familiar shape. The xylazine case study illustrates how laboratories adapted when a veterinary sedative began appearing in forensic specimens. Tianeptine is following a similar arc, with one notable difference: it has been hiding in plain sight on convenience store shelves since at least 2018.
What Tianeptine Is and Why It Matters
Tianeptine is an atypical antidepressant approved in several countries (including France, Russia, and parts of Asia and Latin America) at therapeutic doses on the order of 12.5 mg three times daily. It is not approved by the FDA for any medical use in the United States, is not federally scheduled, and does not meet the statutory definition of a dietary ingredient.
Although structurally related to tricyclic antidepressants, tianeptine’s pharmacology is distinct. At therapeutic and especially supratherapeutic doses, it functions as a mu-opioid receptor (MOR) agonist [1]. This MOR activity explains the opioid-like euphoria reported by users, the abuse potential driving the informal market, and a withdrawal syndrome clinically indistinguishable from opioid withdrawal. So, while “is tianeptine an opioid” is technically no by chemical class, the receptor profile tells a different story functionally.
The May 8, 2025 letter from FDA Commissioner Dr. Martin Makary referenced reported consumer doses of 50 mg to 10,000 mg daily, roughly 1.3 to 250 times the typical foreign therapeutic dose [2].
The Regulatory Landscape: A 2025 Inflection Point
Federal and state activity around tianeptine accelerated sharply in 2025. Three developments are particularly relevant for laboratories planning panel scope:
- FDA Commissioner’s public health letter (May 8, 2025). Commissioner Makary issued a letter warning of growing adverse event reports involving tianeptine products, noting explicitly that tianeptine “may not be identified in routine drug screening panels” [2].
- STAND Against Emerging Opioids Act. Bipartisan legislation reintroduced in May 2025 by Reps. Jimmy Panetta (D-CA) and August Pfluger (R-TX) would classify tianeptine and its analogues as Schedule III under the federal Controlled Substances Act [3].
- State scheduling momentum. More than a dozen states have placed tianeptine under their controlled substances acts, most as Schedule I, with additional state actions in 2024 and 2025 [4]. Connecticut’s Public Act 25-101 directed scheduling alongside six other substances; following an October 2025 public hearing, the regulation took effect March 25, 2026, designating tianeptine as Schedule I [5,6].
As coroner systems and clinical laboratories begin to catalog tianeptine in casework, both retrospective and prospective analytical questions are likely to grow.
Why Many Standard Panels Miss It
This is the heart of the analytical problem. Tianeptine is structurally related to tricyclic antidepressants but it is unlike heroin, fentanyl, or morphine. It is not a phenylpiperidine and not an oripavine alkaloid. It is also not a target on the immunoassays driving many commercial 5-, 10-, and 12-panel urine drug screens.
The practical implication: tianeptine’s mu-opioid pharmacology produces opioid-like clinical effects, but the molecule generally does not cross-react with opioid or fentanyl immunoassays at concentrations encountered in casework. A negative routine UDS does not rule out tianeptine ingestion, and confirmation generally requires targeted LC-MS/MS.
This is a recurring pattern with novel psychoactive substances: clinical presentation reaches the emergency department before laboratory methods catch up. The principles for keeping pace with that gap are explored further in our post on staying ahead of the curve.
The MC5 Metabolite: Why It Matters for Serum and Postmortem Interpretation
Pharmacokinetics complicate interpretation in ways easy to overlook. The parent compound, tianeptine, has an elimination half-life of approximately 2.5 to 3 hours in healthy adults [7]. Its primary active metabolite, MC5 (the pentanoic acid β-oxidation product), has a half-life of approximately 7 to 12 hours, extending to roughly 14 hours in patients with significant renal impairment [7,8].
Two consequences follow:
- Time-of-collection effects. Relying on parent tianeptine alone risks under-detection when time between exposure and specimen collection exceeds several parent half-lives. MC5 persists meaningfully longer, and method development for serum and postmortem casework increasingly favors simultaneous measurement.
- MC5 has its own MOR activity. Beyond serving as a longer-lived analytical marker, MC5 is itself a mu-opioid agonist, with implications for sustained sedation or delayed presentations.
Several published LC-MS/MS methods quantify both tianeptine and MC5 simultaneously, often using deuterated internal standards (tianeptine-D4, MC5-D4) and matrix-matched calibration in plasma, urine, and tissue [7,9].
Practical Considerations for Laboratories Evaluating Tianeptine Addition
The decision to add tianeptine to an expanded opioid or novel psychoactive substance panel is partly analytical and partly operational. A few questions worth working through:
- Casework prevalence. Are tianeptine-related signals showing up in your jurisdiction (poison center calls, ED presentations involving sedation with negative opioid screens, postmortem cases with empty Neptune’s Fix or Tianaa bottles at scene) at a volume that justifies the addition? State scheduling activity in your region is often a leading indicator.
- Method scope. An LC-MS/MS confirmation method for serum, urine, and postmortem applicability should include both tianeptine and MC5 as separate target analytes, with qualifier ions and matrix-matched calibration.
- Co-formulation considerations. The 2023 New Jersey Neptune’s Fix cluster (20 cases through the New Jersey Poison Information and Education System, June–November 2023) documented synthetic cannabinoid receptor agonists, MDMB-4en-PINACA and ADB-4en-PINACA, co-formulated with tianeptine in seized product [10]. Polysubstance ingestion is a real possibility, and parallel SCRA testing may be warranted.
- QC program design. Expanded panels need matched QC at concentrations relevant to clinical (therapeutic and supratherapeutic) and postmortem ranges. Where commercial stock QC availability is limited, Purpose-Built Quality Control is one path forward.
Tianeptine Readiness Checklist
☐ Awareness baseline: Clinical and forensic teams understand that tianeptine is not detected by standard 5-, 10-, or 12-panel UDS.
☐ Confirmation method available: LC-MS/MS panel includes tianeptine, with MC5 as a separate target analyte where serum or postmortem interpretation is needed.
☐ Surveillance signal monitored: Process for tracking poison center, MMWR, CFSRE NPS Discovery, and state scheduling activity quarterly.
☐ Polysubstance scope considered: SCRA and other adulterant capabilities are reviewed in parallel with tianeptine method development.
☐ QC coverage verified: Matrix-matched QC materials are available at concentrations covering both therapeutic and elevated ranges.
Frequently Asked Questions
Does tianeptine show up on a drug test?
Generally, no, not on standard 5, 10, or 12-panel urine drug screens. Tianeptine is not a target on most commercial opioid or tricyclic immunoassays and does not reliably cross-react at clinical or supratherapeutic concentrations. Detection generally requires targeted LC-MS/MS, often as part of an expanded NPS or designer opioid panel.
Is tianeptine an opioid?
By chemical class, no: tianeptine is a tricyclic-related antidepressant. By pharmacology, however, it acts as a mu-opioid receptor agonist, particularly at supratherapeutic doses, producing opioid-like euphoria, dependence, and withdrawal. Many clinicians treat it as an opioid functionally.
What is the half-life of tianeptine?
In healthy adults, the parent compound has an elimination half-life of approximately 2.5 to 3 hours. The active metabolite MC5 has a longer half-life of approximately 7 to 12 hours, extending to roughly 14 hours in patients with renal impairment. MC5 is often the more useful analytical target in serum and postmortem casework.
What testing approach is appropriate for Neptune’s Fix cases?
Targeted LC-MS/MS quantification of both tianeptine and MC5, paired with synthetic cannabinoid receptor agonist screening for known adulterants such as MDMB-4en-PINACA and ADB-4en-PINACA, is the approach reflected in the published New Jersey case series. Treating these cases as polysubstance until confirmed otherwise is generally prudent.
Tianeptine sits in the same category as other emerging compounds laboratories have absorbed into casework over the past five years: present in the supply, present in the clinical picture, but not present on the routine panel. What differs is the speed at which the regulatory environment is moving and the breadth of the consumer-product distribution channels. Laboratories that navigate these shifts most efficiently tend to share a few habits: they monitor surveillance data, keep panel scope under active review, and align QC coverage with what is showing up at the bench.
Evaluating Tianeptine for Your Panel?
If your laboratory is evaluating whether to add tianeptine and MC5 to an expanded opioid or NPS panel, our technical team has worked through these decisions across many laboratory implementations. Reach out at welovecontrol@utak.com or call 888.882.5522 to talk through panel scope, method design, and QC coverage for tianeptine and MC5.
References
1. Gassaway MM, Rives ML, Kruegel AC, Javitch JA, Sames D. The atypical antidepressant and neurorestorative agent tianeptine is a μ-opioid receptor agonist. Translational Psychiatry. 2014;4(7):e411. https://doi.org/10.1038/tp.2014.30
2. U.S. Food and Drug Administration. New “Gas Station Heroin” Tianeptine Product Trend. Letter from Commissioner Martin A. Makary, May 8, 2025. https://www.fda.gov/consumers/health-fraud-scams/new-gas-station-heroin-tianeptine-product-trend
3. Office of Rep. Jimmy Panetta. Rep. Panetta Reintroduces Bipartisan Legislation to Combat Abuse of “Gas Station Heroin” Following FDA Warnings. May 20, 2025. https://panetta.house.gov/media/press-releases/rep-panetta-reintroduces-bipartisan-legislation-combat-abuse-gas-station
4. U.S. Drug Enforcement Administration. Tianeptine Drug Fact Sheet. December 2024. https://www.getsmartaboutdrugs.gov/sites/default/files/2024-12/Tianeptine-Drug-Fact-Sheet.pdf
5. Connecticut Department of Consumer Protection. Public Hearing on Regulation 2025-018 (Scheduling of Tianeptine and Other Substances). October 2025. https://portal.ct.gov/dcp/knowledge-base/articles/public-hearing-on-regulation-2025-018
6. State of Connecticut. Public Act 25-101, Section 4. Designation of Controlled Substances; effective March 25, 2026. https://www.cga.ct.gov/2026/rrdata/pr/2026REG2026-003-PUB.PDF
7. Royer RJ, Albin H, Barrucand D, Salvadori-Failler C, Kamoun A. Pharmacokinetic and metabolic parameters of tianeptine in healthy volunteers and in populations with risk factors. Clinical Neuropharmacology. 1988;11(Suppl 2):S90–S96.
8. Salvadori C, Merdjan H, Brouard R, et al. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis. Fundamental and Clinical Pharmacology. 1990;4:663–671. https://pubmed.ncbi.nlm.nih.gov/2096105/
9. Szafarz M, Wencel A, Pociecha K, et al. Pharmacokinetic study of tianeptine and its active metabolite MC5 in rats following different routes of administration using a novel LC-MS/MS analytical method. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2018;391(2):185–196. https://pubmed.ncbi.nlm.nih.gov/29230490/
10. Counts CJ, Spadaro AV, Cerbini TA, et al. Notes from the Field: Cluster of Severe Illness from Neptune’s Fix Tianeptine Linked to Synthetic Cannabinoids, New Jersey, June–November 2023. MMWR Morbidity and Mortality Weekly Report. 2024;73(4):89–90. https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a5.htm
